The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksN4 Pharma Plc Regulatory News (N4P)

Share Price Information for N4 Pharma Plc (N4P)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.715
Bid: 0.65
Ask: 0.70
Change: 0.09 (14.40%)
Spread: 0.05 (7.692%)
Open: 0.625
High: 0.715
Low: 0.715
Prev. Close: 0.625
N4P Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Update re Investment

4 Apr 2016 08:57

RNS Number : 0259U
Onzima Ventures PLC
04 April 2016
 

Onzima Ventures PLC

("Onzima" or the "Company")

Investee company N4 Pharma announces messenger RNA vaccine program

Onzima is pleased to announce that N4 Pharma Limited ("N4 Pharma") its 49%-owned investee company, has extended its relationship with the University of Queensland ("Uniquest") to include the exclusive global rights to commercialise their nano particle vaccine delivery system for messenger RNA (mRNA) particles. This adds to the rights it already has for plasmid DNA and certain subunit vaccines.

Under this agreement N4 Pharma will undertake further research and experimentation with Uniquest to develop a strong in-vitro data package demonstrating the ability of these vectors to achieve high protective loading of pDNA and mRNA and demonstrate their strong transfection capability.

N4 Pharma CEO Nigel Theobald commented:

"mRNA is an exciting area of therapeutic treatment in oncology and early encouraging results with our plasmid DNA research show strong pDNA loading onto the silica vesicle and excellent transfection being achieved.

Over the next few months we will continue to undertake experiments to demonstrate the capability of our vectors for both pDNA and mRNA, publishing the data when we can with a view to looking to engage with potential partners in the second half of 2016 to either work with their own particles or potentially acquire the rights to particles ourselves which we can then seek to take forward using these vectors.

The recent investment by Onzima Ventures has allowed us to develop our intellectual property portfolio and create two extremely strong drug delivery/reformulation platforms, one for small molecules and another for vaccines and oncology treatments. Our aim now is to develop strong commercial propositions using our IP and seek partnerships and funds to take forward specific projects."

For further information please contact:

Onzima Ventures PLC Tel: +44 (0) 1622 717700

Gavin Burnell, Luke Cairns

 

Nominated Adviser

Cairn Financial Advisers LLP Tel: +44 (0) 20 7148 7900

Sandy Jamieson, Liam Murray

 

Broker

Peterhouse Corporate Finance Limited Tel: +44 (0) 20 7469 0930

Guy Miller, Lucy Williams

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCEAXLLESLKEEF
Date   Source Headline
24th Sep 20182:05 pmRNSSecond Price Monitoring Extn
24th Sep 20182:00 pmRNSPrice Monitoring Extension
24th Sep 20187:00 amRNSAcceptance of Nuvec® on EUNCL
20th Sep 20187:01 amRNSInterim Results
20th Sep 20187:00 amRNSStrategic Review
30th Jul 201811:05 amRNSSecond Price Monitoring Extn
30th Jul 201811:00 amRNSPrice Monitoring Extension
30th Jul 20187:00 amRNSChange of Adviser
17th Jul 20181:12 pmRNSHolding(s) in Company
11th Jul 20182:05 pmRNSSecond Price Monitoring Extn
11th Jul 20182:00 pmRNSPrice Monitoring Extension
9th Jul 20187:00 amRNSClinical trials preliminary results
18th Jun 20187:00 amRNSNuvec® Update
23rd May 201811:31 amRNSResult of AGM
9th May 20187:00 amRNSFiling of Patent
27th Apr 201811:00 amRNSPosting of Annual Report and Notice of AGM
25th Apr 20187:00 amRNSFinal Results
18th Apr 20187:00 amRNSCommencement of Sildenafil Clinical Trial
9th Apr 201811:00 amRNSPrice Monitoring Extension
9th Mar 20188:43 amRNSExercise of Warrants and Total Voting Rights
8th Mar 201810:05 amRNSHolding(s) in Company
8th Mar 20187:00 amRNSNuvec® Update
7th Mar 20188:33 amRNSExercise of Warrants and Total Voting Rights
2nd Mar 201812:17 pmRNSChange of Adviser
26th Feb 20189:27 amRNSExercise of Warrants and Total Voting Rights
21st Feb 20181:36 pmRNSExercise of Warrants and Total Voting Rights
19th Feb 20185:01 pmRNSExercise of Warrants and Total Voting Rights
14th Feb 20185:26 pmRNSExercise of Warrants and Total Voting Rights
13th Feb 201812:52 pmRNSExercise of Warrants and Total Voting Rights
12th Feb 20182:05 pmRNSSecond Price Monitoring Extn
12th Feb 20182:00 pmRNSPrice Monitoring Extension
12th Feb 201811:06 amRNSSecond Price Monitoring Extn
12th Feb 201811:00 amRNSPrice Monitoring Extension
8th Feb 201812:01 pmRNSHolding(s) in Company
8th Feb 201811:46 amRNSExercise of Warrants and Total Voting Rights
5th Feb 20187:00 amRNSIssue of Equity and Director/PDMR Shareholding
2nd Feb 20184:47 pmRNSExercise of Warrants and Total Voting Rights
2nd Feb 20181:04 pmRNSAward of Grant and Collaboration with MedImmune UK
30th Jan 20183:04 pmRNSExercise of Warrants and Total Voting Rights
24th Jan 20184:06 pmRNSExercise of Warrants and Total Voting Rights
24th Jan 20181:19 pmRNSGlobal Business Accelerator Programme in Japan
22nd Jan 201810:44 amRNSExercise of Warrants and Total Voting Rights
15th Jan 201812:36 pmRNSHolding(s) in Company
8th Jan 20182:31 pmRNSExercise of Warrants and Total Voting Rights
8th Jan 20181:26 pmRNSHolding(s) in Company
28th Dec 20179:03 amRNSExercise of Warrants and Total Voting Rights
22nd Dec 20177:00 amRNSFiling of Patent
18th Dec 20178:27 amRNSHolding(s) in Company
13th Dec 20174:07 pmRNSExercise of Warrants and Total Voting Rights
29th Nov 201711:12 amRNSViagra switch to OTC status in the UK

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.